Executive Summary The pharmaceutical industry’s revenue engine runs on a single legal mechanism: the patent. Strip away the marketing language […]
When Do Drug Patents Expire: Understanding the Lifecycle of Pharmaceutical Innovations Read Post »
1. Why PTE Is a Financial Asset, Not an Administrative Checkbox A single additional day of patent exclusivity on Keytruda
Executive Summary Three decades of aggressive outsourcing to low-cost geographies suppressed the Cost of Goods Sold (COGS) for Active Pharmaceutical
KSM Sourcing for Pharmaceutical APIs: The Definitive Playbook Read Post »
Section 1: The Patent Cliff, Defined and Reframed What the Term Actually Means The phrase ‘patent cliff’ describes the sharp
Why Generic Drug Market Analysis Fails — and How to Fix It Most generic drug market analyses make the same
A deep-dive pillar for pharma IP teams, generic market strategists, portfolio managers, and institutional investors tracking ANDA timelines and biosimilar
REMS Weaponized: How Brand Pharma Turns Safety Programs Into $13.4B Competition Shields Read Post »
1. Eroom’s Law, the $2.6 Billion Problem, and Why Traditional R&D Has Stopped Working Jack Scannell named Eroom’s Law in
Executive Summary The global generic drug market sits at an unusual intersection: structural demand that will not shrink, a near-term
The generic pharmaceutical industry has a problem it created for itself. For decades, the dominant growth strategy was volume: file
Sign in or create a free account to read this DrugPatentWatch article
